CFB
ELV icon

Cullen/Frost Bankers’s Elevance Health ELV Stock Holding History

Cullen/Frost Bankers’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Buy
27,444
+8,747
+47% +$3.24M 0.1% 173
2026
Q1 		$5.47M Buy
18,697
+162
+0.9% +$53.2K 0.06% 208
2025
Q4 		$6.5M Sell
18,535
-1,971
-10% -$666K 0.07% 200
2025
Q3 		$6.63M Sell
20,506
-1,339
-6% -$416K 0.08% 192
2025
Q2 		$8.5M Buy
21,845
+854
+4% +$344K 0.11% 171
2025
Q1 		$9.13M Sell
20,991
-288
-1% -$116K 0.13% 154
2024
Q4 		$7.85M Sell
21,279
-1,148
-5% -$480K 0.11% 168
2024
Q3 		$11.7M Buy
22,427
+1,894
+9% +$1.01M 0.16% 135
2024
Q2 		$11.1M Sell
20,533
-480
-2% -$254K 0.16% 135
2024
Q1 		$10.9M Sell
21,013
-210
-1% -$104K 0.16% 145
2023
Q4 		$10M Sell
21,223
-213
-1% -$98.5K 0.16% 149
2023
Q3 		$9.33M Buy
21,436
+663
+3% +$301K 0.16% 143
2023
Q2 		$9.23M Sell
20,773
-225
-1% -$104K 0.16% 146
2023
Q1 		$9.66M Sell
20,998
-11,169
-35% -$5.32M 0.18% 142
2022
Q4 		$16.5M Buy
32,167
+17,202
+115% +$8.73M 0.31% 93
2022
Q3 		$6.8M Sell
14,965
-6,441
-30% -$3.08M 0.16% 144
2022
Q2 		$10.3M Sell
21,406
-39
-0.2% -$19.3K 0.23% 109
2022
Q1 		$10.5M Buy
21,445
+751
+4% +$343K 0.21% 120
2021
Q4 		$9.59M Sell
20,694
-1,382
-6% -$581K 0.18% 125
2021
Q3 		$8.23M Sell
22,076
-360
-2% -$137K 0.17% 137
2021
Q2 		$8.57M Sell
22,436
-1,018
-4% -$389K 0.17% 130
2021
Q1 		$8.42M Buy
23,454
+680
+3% +$219K 0.18% 127
2020
Q4 		$7.31M Sell
22,774
-1,109
-5% -$340K 0.17% 134
2020
Q3 		$6.42M Sell
23,883
-1,286
-5% -$346K 0.16% 132
2020
Q2 		$6.62M Sell
25,169
-3,414
-12% -$911K 0.17% 123
2020
Q1 		$6.49M Sell
28,583
-3,424
-11% -$933K 0.23% 114
2019
Q4 		$9.67M Sell
32,007
-1,781
-5% -$490K 0.26% 106
2019
Q3 		$8.11M Sell
33,788
-898
-3% -$246K 0.24% 114
2019
Q2 		$9.79M Sell
34,686
-944
-3% -$258K 0.3% 100
2019
Q1 		$10.2M Sell
35,630
-573
-2% -$166K 0.31% 104
2018
Q4 		$9.51M Buy
+36,203
New +$9.95M 0.35% 96

Other funds holding ELV

HGIM
High Ground Investment Management London, United Kingdom $1.14B AUM 29.32% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CF
Canoe Financial Calgary, Alberta, Canada $8.07B AUM 25.47% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MIHAS
Maj Invest Holding A/S Copenhagen K, Denmark $2.2B AUM 25.64% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
MR
Munich Reinsurance Munich $4.57B AUM 28.39% 1-Year Est. Return

Cullen/Frost Bankers's ELV Position: Q2 2026 in Review

Cullen/Frost Bankers increased its Elevance Health (ELV) stake by 47% in Q2 2026, buying an estimated $3.24M and bringing the position to 27,444 shares worth $10.6M. The position accounts for 0.1% of the portfolio, ranked #173.

Cullen/Frost Bankers first reported a position in ELV in Q4 2018 and has held it in 31 quarters since. The position peaked at $16.5M in Q4 2022. 460 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Cullen/Frost Bankers held 27,444 shares of Elevance Health worth $10.6M as of Q2 2026.
  • Cullen/Frost Bankers bought 8,747 Elevance Health shares in Q2 2026, an estimated $3.24M.
  • Elevance Health made up 0.1% of Cullen/Frost Bankers's portfolio in Q2 2026, its #173 holding.
  • Cullen/Frost Bankers first reported a position in Elevance Health in Q4 2018 and has held it in 31 quarters since.
  • Cullen/Frost Bankers's Elevance Health position peaked at $16.5M in Q4 2022.
  • 460 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.